Gilead challenges Baraclude
Published: 2012-11-23 07:00:00
Updated: 2012-11-23 07:00:00
Gilead Sciences, Inc., a developer of Viread (tenofovir disoproxil fumarate), is poised to enter the 200 billion won anti-hepatitis B drug market here, which has been dominated by BMS Korea’s Baraclude (entecavir).
Baraclude is an oral antiviral drug used in the treatment of chronic hepatitis ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
